Back to News
Oct 23, 2025 12:00 PM

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Efficacy Results Across Study Indications:

As of September 1, 2025, 179 patients were enrolled across all histologies, with 154 at active doses (200 mg and above).

94 tumor evaluable patients were enrolled more than 6 months before the efficacy analysis and included regardless of outcome.

Across cancer types overall response rate (ORR) was 27%, the disease control rate (DCR) was 78% and the median progression-free survival (mPFS) was 6.4 months.

37 of 94 patients remained on treatment as of September 1, 2025.

Also Read: Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data